Wong, Kit Man
King, Gentry G.
Harris, William P.
Article History
Accepted: 10 January 2022
First Online: 26 March 2022
Declarations
:
: Kit Man Wong has received institutional research funding from Genentech, Exelixis, Shanghai De Novo Pharmatech, Adaptimmune Therapeutics, Pfizer, Astellas, Replimune, Mitsubishi Tanabe Pharma, Eli Lilly, and AstraZeneca and has received compensation for participation on advisory boards from Genentech, Exelixis, and HalioDX. Gentry G. King has received institutional funding for clinical trials from Bayer; has received compensation for service as a consultant from Zymeworks and Tempus; has received compensation for participation on advisory boards from Pfizer and QED Therapeutics; has received speaker’s honoraria from the Society for Immunotherapy of Cancer (SITC) and the International Society of Gastrointestinal Oncology (IGSIO); received reimbursement for travel/accommodations from the IGSIO; is member of the National Cancer Institute (NCI) Hepatobiliary Task Force and Southwest Oncology Group; and is Co-Chair of the ctDNA GI Steering Committee. William P. Harris has received institutional research funding from Exelixis, Bristol-Myers Squibb, MedImmune, AstraZeneca, Bayer, Boston Scientific, Merck, Koo Foundation, and Zymeworks; has received compensation for service as a consultant from Zymeworks, Merck, and BD Medical; has received compensation for participation on advisory boards from Exelixis, AstraZeneca, and Eisai; and serves on the Board of Directors (unpaid) of the GI Cancers Alliance.